Knowledge Center
20 December 2024
Navigating the Risks: Why Compassionate Use Should Not Replace Rigorous Clinical Trials
Recently, we have observed an increasing number of queries from clients exploring the potential of utilizing 'special access-like schemes' to obtain clinical data, as an alternative to conducting properly structured clinical trials, due to challenges in securing necessary funding.
4 December 2024
Accessing Unapproved Therapeutic Modalities in the USA and Australia
Both the United States and Australia have established regulatory frameworks to address these needs, governed by the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), respectively.
19 November 2024
Demystifying Cell and Gene Therapy Studies in Australia and the Broader APAC Region
The global cell and gene therapy (CGT) industry continues to accelerate, thanks to its potential to generate life-changing treatments across a range of chronic indications, including cancers and rare diseases.
10 October 2024
How Avance Clinical’s In-house ClinicReady Service Supports Early-Stage Biotech Companies to Secure Funding
For early-stage biotech companies, securing funding is often a significant challenge due to the complex and costly nature of drug development. Avance Clinical, a leading contract research organization (CRO), offers tailored consultancy services to help biotech companies navigate the investment process to bring their innovations to market.
2 September 2024
The Asia Advantage: Why US Biotechs Should Look East for Clinical Trials
This article explores the compelling reasons behind the Asia Advantage and highlights how Avance Clinical's strategic expansion into the region supports biotechs in maximizing these benefits.
17 August 2024
Leveraging a Global Site Partnership Network: Accelerating Study Start-up and Patient Recruitment for Successful Clinical Trials
A network of proven and trusted sites means sponsors can progress quickly through the site selection process to study startup and then be assured of reliable patient recruitment and robust data.
12 July 2024
What is The Australian Advantage: How does it maximize Benefits for US Biotechs?
This approach offers US biotech firms numerous benefits, including a cash rebate of almost 50%, faster timelines, no IND requirement, and globally accepted data.
25 June 2024
Unveiling the Potential of Psychedelic Therapies: Key Insights for Biotech Decision Makers
The rapidly evolving field of psychedelic therapies offers a promising frontier for medical research, particularly in treating mental health and neurodegenerative diseases.
Proven industry
experience & expertise
500+
Studies in the past 5 years
450+
Experienced team members
18k+
Participants past 5 years
30
Years of CRO experience